TRIVASTAL Sustained release coated tablet Ref.[8857] Active ingredients: Piribedil

Source: Web Search  Revision Year: 2013  Publisher: Les Laboratoires Servier

Therapeutic indications

Treatment of Parkinson’s disease:

  • either as monotherapy,
  • or combined with dopatherapy from the onset, or secondarily.

Posology and method of administration

Oral route.

Treatment of Parkinson’s disease:

  • as monotherapy: 150 mg to 250 mg, i.e. 3 to 5 tablets per day, to be divided into 3 to 5 administrations per day.
  • as a supplement to dopatherapy: 80 to 140 mg (approximately 20 mg of piribedil per 100 mg of L. Dopa). Given the dose division, the tablet containing 20 mg of piribedil is more suitable.

The tablets are to be swallowed with a half-glass of water, without chewing, at the end of meals.

These doses must be attained gradually: increase by one tablet every three days.

Overdose

Given the emetic effect of piribedil at very high doses, overdosage is unlikely with the tablet form.

The signs of overdose are:

  • blood pressure instability (arterial hypertension or hypotension),
  • digestive symptoms (nausea, vomiting).

These symptoms disappear on discontinuation of administration and with symptomatic treatment.

Shelf life

3 years.

Special precautions for storage

Store below 30°C.

Nature and contents of container

10, 20, 30, 40, 50, 60 or 100 tablets in blisters (PVC/Aluminium).

Special precautions for disposal and other handling

LES LABORATOIRES SERVIER

< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈